Logo image of ANRO

ALTO NEUROSCIENCE INC (ANRO) Stock Fundamental Analysis

NYSE:ANRO - New York Stock Exchange, Inc. - US02157Q1094 - Common Stock - Currency: USD

2.49  -0.11 (-4.23%)

Fundamental Rating

2

ANRO gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 195 industry peers in the Pharmaceuticals industry. The financial health of ANRO is average, but there are quite some concerns on its profitability. ANRO has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ANRO has reported negative net income.
In the past year ANRO has reported a negative cash flow from operations.
ANRO Yearly Net Income VS EBIT VS OCF VS FCFANRO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

ANRO has a Return On Assets (-36.75%) which is in line with its industry peers.
ANRO has a Return On Equity (-45.42%) which is in line with its industry peers.
Industry RankSector Rank
ROA -36.75%
ROE -45.42%
ROIC N/A
ROA(3y)-43.67%
ROA(5y)N/A
ROE(3y)-58.16%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ANRO Yearly ROA, ROE, ROICANRO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ANRO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ANRO Yearly Profit, Operating, Gross MarginsANRO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 -1K -2K -3K -4K -5K

More info and screens

5

2. Health

2.1 Basic Checks

The number of shares outstanding for ANRO has been increased compared to 1 year ago.
ANRO has a better debt/assets ratio than last year.
ANRO Yearly Shares OutstandingANRO Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 5M 10M 15M 20M 25M
ANRO Yearly Total Debt VS Total AssetsANRO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

ANRO has an Altman-Z score of -0.21. This is a bad value and indicates that ANRO is not financially healthy and even has some risk of bankruptcy.
ANRO has a Altman-Z score (-0.21) which is in line with its industry peers.
A Debt/Equity ratio of 0.15 indicates that ANRO is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.15, ANRO is in line with its industry, outperforming 46.15% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF N/A
Altman-Z -0.21
ROIC/WACCN/A
WACCN/A
ANRO Yearly LT Debt VS Equity VS FCFANRO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

ANRO has a Current Ratio of 22.53. This indicates that ANRO is financially healthy and has no problem in meeting its short term obligations.
ANRO has a Current ratio of 22.53. This is amongst the best in the industry. ANRO outperforms 91.28% of its industry peers.
ANRO has a Quick Ratio of 22.53. This indicates that ANRO is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 22.53, ANRO belongs to the top of the industry, outperforming 91.28% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 22.53
Quick Ratio 22.53
ANRO Yearly Current Assets VS Current LiabilitesANRO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 50M 100M 150M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for ANRO have decreased strongly by -75.89% in the last year.
EPS 1Y (TTM)-75.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26.32%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ANRO will show a decrease in Earnings Per Share. The EPS will decrease by -6.86% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-2.49%
EPS Next 2Y-7.41%
EPS Next 3Y-6.86%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ANRO Yearly Revenue VS EstimatesANRO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 50K 100K 150K 200K
ANRO Yearly EPS VS EstimatesANRO Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ANRO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ANRO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ANRO Price Earnings VS Forward Price EarningsANRO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ANRO Per share dataANRO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

ANRO's earnings are expected to decrease with -6.86% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-7.41%
EPS Next 3Y-6.86%

More info and screens

0

5. Dividend

5.1 Amount

ANRO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALTO NEUROSCIENCE INC

NYSE:ANRO (6/3/2025, 11:54:45 AM)

2.49

-0.11 (-4.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-14 2025-05-14/amc
Earnings (Next)N/A N/A
Inst Owners88.31%
Inst Owner Change-7.88%
Ins Owners7.51%
Ins Owner Change0%
Market Cap67.40M
Analysts85.71
Price Target11.73 (371.08%)
Short Float %12.13%
Short Ratio12.56
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)12.62%
Min EPS beat(2)9.7%
Max EPS beat(2)15.54%
EPS beat(4)4
Avg EPS beat(4)11.1%
Min EPS beat(4)6.96%
Max EPS beat(4)15.54%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-2.54%
EPS NQ rev (1m)1.9%
EPS NQ rev (3m)4.96%
EPS NY rev (1m)4.31%
EPS NY rev (3m)-0.76%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.48
P/tB 0.48
EV/EBITDA N/A
EPS(TTM)-2.34
EYN/A
EPS(NY)-2.93
Fwd EYN/A
FCF(TTM)-2.03
FCFYN/A
OCF(TTM)-1.96
OCFYN/A
SpS0
BVpS5.14
TBVpS5.14
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -36.75%
ROE -45.42%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-43.67%
ROA(5y)N/A
ROE(3y)-58.16%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 325.52%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 22.53
Quick Ratio 22.53
Altman-Z -0.21
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)251.13%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-75.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26.32%
EPS Next Y-2.49%
EPS Next 2Y-7.41%
EPS Next 3Y-6.86%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-81.46%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-15.77%
EBIT Next 3Y-23.96%
EBIT Next 5YN/A
FCF growth 1Y-45.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-41.78%
OCF growth 3YN/A
OCF growth 5YN/A